Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

37 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Randomised study of tegafur and oral leucovorin versus intravenous 5-fluorouracil and leucovorin in patients with advanced colorectal cancer.
Nogué M, Salud A, Batiste-Alentorn E, Saigí E, Losa F, Cirera L, Méndez M, Campos JM, Galan A, Escudero P, Arcusa A, Manzano H, de Mendizábal EV, de Olaguer JP, Boleda M, Guasch I, Vicente P. Nogué M, et al. Among authors: saigi e. Eur J Cancer. 2005 Oct;41(15):2241-9. doi: 10.1016/j.ejca.2005.07.013. Eur J Cancer. 2005. PMID: 16214045 Clinical Trial.
Phase II study of irinotecan (CPT-11) administered every 2 weeks as treatment for patients with colorectal cancer resistant to previous treatment with 5-fluorouracil-based therapies: comparison of two different dose schedules (250 and 200 mg/m2) according to toxicity prognostic factors.
Saigi E, Salut A, Campos JM, Losa F, Manzano H, Batiste-Alentorn E, Acusa A, Vélez de Mendizabal E, Guasch I, Antón I; ACROSS Cooperative Group. Saigi E, et al. Anticancer Drugs. 2004 Oct;15(9):835-41. doi: 10.1097/00001813-200410000-00003. Anticancer Drugs. 2004. PMID: 15457123 Clinical Trial.
Biweekly cetuximab in combination with FOLFOX-4 in the first-line treatment of wild-type KRAS metastatic colorectal cancer: final results of a phase II, open-label, clinical trial (OPTIMIX-ACROSS Study).
Fernandez-Plana J, Pericay C, Quintero G, Alonso V, Salud A, Mendez M, Salgado M, Saigi E, Cirera L; ACROSS Study Group. Fernandez-Plana J, et al. Among authors: saigi e. BMC Cancer. 2014 Nov 22;14:865. doi: 10.1186/1471-2407-14-865. BMC Cancer. 2014. PMID: 25417182 Free PMC article. Clinical Trial.
Analysis of the pathologic response to primary chemotherapy in patients with locally advanced breast cancer grouped according to estrogen receptor, progesterone receptor, and HER2 status.
Fernández-Morales LA, Seguí MA, Andreu X, Dalmau E, Sáez A, Pericay C, Santos C, Montesinos J, Gallardo E, Arcusa A, Saigí E. Fernández-Morales LA, et al. Among authors: saigi e. Clin Breast Cancer. 2007 Apr;7(7):559-64. doi: 10.3816/CBC.2007.n.012. Clin Breast Cancer. 2007. PMID: 17509165 Clinical Trial.
Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial.
Davies C, Pan H, Godwin J, Gray R, Arriagada R, Raina V, Abraham M, Medeiros Alencar VH, Badran A, Bonfill X, Bradbury J, Clarke M, Collins R, Davis SR, Delmestri A, Forbes JF, Haddad P, Hou MF, Inbar M, Khaled H, Kielanowska J, Kwan WH, Mathew BS, Mittra I, Müller B, Nicolucci A, Peralta O, Pernas F, Petruzelka L, Pienkowski T, Radhika R, Rajan B, Rubach MT, Tort S, Urrútia G, Valentini M, Wang Y, Peto R; Adjuvant Tamoxifen: Longer Against Shorter (ATLAS) Collaborative Group. Davies C, et al. Lancet. 2013 Mar 9;381(9869):805-16. doi: 10.1016/S0140-6736(12)61963-1. Lancet. 2013. PMID: 23219286 Free PMC article. Clinical Trial.
37 results